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Abstract  
 
Aims Because low-grade inflammation may play a role in the pathogenesis of coronary heart 
disease (CHD), and pro-inflammatory cytokines govern inflammatory cascades, this study 
aimed to assess the associations of several pro-inflammatory cytokines and CHD risk in a new 
prospective study, including meta-analysis of prospective studies. 
 
Methods and Results Interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinase-9 
(MMP-9), soluble CD40 ligand (sCD40L), and tumour necrosis factor–alpha (TNF-α) were 
measured at baseline in a case-cohort study of 1514 participants and 833 incident CHD events 
within population-based prospective cohorts at the Danish Research Centre for Prevention and 
Health. Age- and sex-adjusted hazard ratios (HR) for CHD per 1-SD higher log-transformed 
baseline levels were: 1.37 (95% CI, 1.21-1.54) for IL-6, 1.26 (1.11-1.44) for IL-18, 1.30 
(1.16-1.46) for MMP-9, 1.01 (0.89-1.15) for sCD40L, and 1.13 (1.01-1.27) for TNF-α. 
Multivariable adjustment for conventional vascular risk factors attenuated the HRs to: 1.26 
(1.08-1.46) for IL-6, 1.12 (0.95-1.31) for IL-18, 1.21 (1.05-1.39) for MMP-9, 0.93 (0.78-1.11) 
for sCD40L, and 1.14 (1.00-1.31) for TNF-α. In meta-analysis of up to 29 population-based 
prospective studies, adjusted relative risks for non-fatal MI or CHD death per 1-SD higher 
levels were: 1.25 (1.19-1.32) for IL-6; 1.13 (1.05-1.20) for IL-18; 1.07 (0.97-1.19) for MMP-
9; 1.07 (0.95-1.21) for sCD40L and 1.17 (1.09-1.25) for TNF-α.  
 
Conclusions Several different pro-inflammatory cytokines are each associated with CHD risk 
independent of conventional risk factors and in an approximately log-linear manner. The 
findings lend support to the inflammation hypothesis in vascular disease, but further studies 
are needed to assess causality.  
 
Keywords Inflammation, CHD, Cytokines, Risk factors, Meta-analysis 
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Introduction 
As inflammatory processes may play an important role in the pathogenesis of vascular 
disease,1, 2 there is interest in the relevance of circulating markers of inflammation to coronary 
heart disease (CHD). Previous epidemiological studies have mainly reported on associations 
between “downstream” markers of inflammation (eg C-reactive protein [CRP] and fibrinogen) 
with the risk of incident CHD.3, 4 However, human genetic evidence has reduced the likelihood 
that these liver-derived factors are causally relevant.5-7 By contrast, “upstream” markers of 
inflammation, such as pro-inflammatory cytokines, may be more likely to be directly 
etiologically relevant to CHD because they govern inflammation cascades.8 Most 
epidemiological evidence on the relevance of such markers has been obtained for interleukin-6 
(IL-6).9 Previous work has suggested that long-term soluble IL-6 levels are associated with 
CHD risk about as strongly as some major established risk factors,9 and a causal role for IL-6 
signaling in CHD has been supported by human genetic evidence.10, 11 These findings have 
intensified interest in recently launched large-scale phase 3 clinical trials of various anti-
inflammatory agents in the secondary prevention of cardiovascular disease (CVD).12, 13 
 
However, in contrast with IL-6, other further upstream markers of the inflammatory response 
have been less well studied (eTable 1). These include factors which are involved in vascular 
inflammation and which are produced mainly by cells of the innate immune system, such as 
interleukin-18 (IL-18)14 and matrix metalloproteinase-9 (MMP-9),15 and factors that are also 
produced by cells of the adaptive immune system, such as soluble CD40 ligand (sCD40L),16 
and tumour necrosis factor–alpha (TNF-α).17 So far, direct comparison between the markers 
has been difficult, because the individual markers have not been measured in the same studies 
or participants. Furthermore, there is little information about the extent to which these 
analytes fluctuate within individuals over time, as such data are essential to the interpretation 
of epidemiological studies with an etiological motivation. 
 
We report new findings on the association of the above five inflammatory markers and incident 
CHD outcomes based on data from population-based prospective cohorts at the Danish 
Research Centre for Prevention and Health (RCPH),18 comprising a total of 1514 participants 
aged 30-70 years at baseline and an average of follow-up of 12 years. Furthermore, we used 
data from serial measurements of these cytokines from two other prospective studies 
(Reykjavik9 and British Regional Heart Study16, 17, 19, 20) to assess long-term within person 
variability. Finally, to contextualise our findings, we also report an updated systematic review 
and meta-analyses of the association of these cytokines and non-fatal MI or CHD death in 
population-based prospective studies.  
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Methods  
Participants 
We measured circulating levels of IL-6, IL-18, MMP-9, sCD40L, and TNF-α in a case-cohort 
study nested within population-based prospective cohorts at the Danish Research Centre for 
Prevention and Health (RCPH). Details of the RCPH cohorts have been described previously.18 
By 2001 the study comprised 8,314 participants from 5 cohorts in the south-western part of 
Copenhagen county (eTable 2): (i) 70 year olds from the 1914 birth-cohort (70yr1914, 
n=992) (ii) 45 year olds from the 1936 birth-cohort (45yr1935, n=804) (iii) 5-year re-
examination of the first Dan-MONICA cohort (GenMon, n=2987) (iv) the second Dan-MONICA 
cohort (MONICAII, n=1504) and (v) the third Dan-MONICA cohort (MONICAIII, n=2027). 
Standardised methods for follow up and risk factor assessment have been maintained in these 
5 cohorts.18 Our case-cohort study of inflammatory cytokines included all incident CHD cases 
(defined using ICD8 codes 410-414  or ICD10 codes I20-I25) recorded as of 31st December 
2006, plus sub-cohorts of randomly sampled participants within each cohort (7% in each of 
45yr1936, MONICAII, and MONICAIII; 9% in GenMon; and 28% in 70yr1914; reflecting the 
proportion of CHD cases within each cohort) for a total of 1514 participants aged 30-70 years 
(eTable 2). In total there were 833 incident CHD cases (comprising 320 non-fatal MI, 195 
CHD deaths, and 318 angina - eTable 2). The study complies with the Declaration of Helsinki 
and was approved by the ethical committee of the county of Copenhagen. 
Biochemical measurements 
Blood samples were drawn after 8-12 hours of fasting and stored at -20 °C before 
measurements of pro-inflammatory cytokines in November 2008 (mean storage duration = 22 
years). Assays of IL-6,9 IL-18,17 MMP-9,15 sCD40L,16 and TNF-α17 were performed centrally at 
the University of Glasgow laboratory using high-sensitivity ELISAs (R & D systems, Abingdon, 
UK) as previously reported.9, 15-17 Intra- and inter-assay coefficients of variation were 7.0 and 
8.0% (IL-6); 5.6 and 10.4% (IL-18); 4.4 and 10.4% (MMP-9); 2.9 and 14.9% (sCD40L); and 
8.4 and 12.5% (TNF-α) respectively.9, 15, 17 Participants from the MONICA II cohort were 
excluded from the analyses of sCD40L due to technical pre-analytical issues related to sample 
handling (previous thawing and freezing) that led to erroneous low values of the sCD40L 
assay. CRP measurements were later done in another laboratory (MORGAM) using serum 
samples that remained available in three of the RCPH cohorts (55% of participants in the 
GenMon cohort and all participants in the MONICAII and MONICAIII cohorts). Measurements of 
other biochemical factors involved standard methods as described previously.21  
Outcomes 
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Assessment of the cardiovascular endpoints was based on data from the Danish National 
Patient Registry (DNPR)22 and the Danish Register of Causes of Death (DRCD).23 Individuals 
who had died or emigrated were identified through the Central Population Registry of Statistics 
Denmark. Linkage between population surveys and national registries are made possible due 
to a unique individual ten digit code. The primary endpoint in the design of our study was pre-
specified as the composite of all CHD outcomes (including non-fatal MI, fatal CHD, and angina) 
in order to enhance statistical power. The composite of non-fatal MI and fatal CHD was 
analysed as a secondary endpoint. Participants with pre-existing CHD at baseline were 
excluded from all analyses to avoid reverse association bias. While specific validation of 
endpoints against coding in the DNPR and DRCD national registers was not conducted in the 
current study, previous validation studies of the same registers have found excellent 
completeness and validity of recorded diagnosis of myocardial infarction (positive predictive 
value [PPV] = 82% overall, and 92% if associated with a ward diagnosis) although less so for 
diagnosis of unstable angina pectoris (PPV = 28% overall).24, 25         
Statistical analyses 
As none of the inflammatory cytokines studied were normally distributed, natural logarithm 
(loge) transformed values of each cytokine were used for all analyses. Partial correlation 
coefficients (adjusted for cohort, age, and sex) were calculated to assess the correlation 
between inflammatory markers and continuous vascular risk factors, whereas mean differences 
between groups were calculated for categorical factors. Analyses of the associations between 
inflammatory cytokines and CHD outcomes involved weighted Cox-regression modelling, using 
the Barlow weighting method to account for the case-cohort study design.26, 27. Shapes of 
association were assessed by plotting hazard ratios (HRs) estimated within quintiles of each 
cytokine relative to the bottom quintile against the mean cytokine level in each quintile. 95% 
confidence intervals (CI) were estimated from variances attributed to the groups to reflect the 
amount of information within each group (including the reference category).28 To assess the 
independence of association between each cytokine and CHD, we calculated HRs per 1-SD 
higher baseline levels with progressive adjustment of baseline levels of potential confounders. 
The use of 1-SD higher HRs also facilitated direct comparison of the strength of association 
across the 5 cytokines. All analyses were stratified by cohort and a 2-sided p-value <0.05 was 
considered statistically significant. 
Literature review and meta-analysis 
Prospective studies of the association between any of the 5 cytokines and risk of non-fatal MI 
or CHD death that were published before 31 December 2012 were sought using computer-
based databases (MEDLINE, EMBASE, and Science Citation Index), by scanning the reference 
lists of articles identified for all relevant studies and review articles (including meta-analyses) 
and hand searching of relevant journals, without language restriction. The computer-based 
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searches combined free and MeSH search terms and combinations of key words related to the 
cytokines (e.g., ‘‘interleukin-6’’, ‘‘IL-6’’, “interleukin-18”, “IL-18”, “matrix metalloproteinase-
9”, “MMP-9”, “soluble CD40 ligand”, “sCD40L”, “tumour necrosis factor–alpha”,  “TNF-alpha”) 
and coronary disease (e.g.,‘‘coronary heart disease’’, ‘‘myocardial ischemia’’, ‘‘myocardial 
infarction’’, ‘‘CHD’’, ‘‘heart attack’’, ‘‘MI’’) without restricting language or publication date. 
Studies were eligible for inclusion if they had at least one year of follow-up; had recruited 
participants from approximately general populations (i.e., did not select participants on the 
basis of pre-existing disease at baseline); and had assessed non-fatal MI or CHD death as 
outcome. Study level characteristics and participant characteristics were extracted using a 
standardised data extraction form, including information on: geographic location, publication 
date, sample population, sampling methods (i.e., complete, random, etc.), years of baseline 
survey, number of participants, number of non-fatal MI or CHD death cases, age range or 
mean age, percentage of males, duration of follow up, and assay/sample characteristics 
(including source, type, sample storage, sample type and fasting status). Also extracted were 
the reported measures of association (i.e. hazard ratios, odds ratios, or other measure of 
relative risk) and their confidence intervals or standard errors, units of comparison, and degree 
of adjustment for confounders. Information from multivariable models adjusted for 
conventional risk factors for CHD was prioritised for inclusion in the meta-analysis (as opposed 
to models further adjusted for inflammatory markers or socio-economic variables, as such 
information was more limited within studies). The reported relative risks were standardised to 
correspond to comparison of relative risk (RR) per 1-SD higher values of each cytokine,9, 29 and 
were pooled across studies using random-effects meta-analysis. Heterogeneity between 
studies was quantified using the I2 statistic.30 Potential publication and small-study bias was 
visually assessed from funnel plots, complemented by formal statistical tests of funnel plot 
asymmetry and use of trim and fill procedure to assess impact.31 For IL-6, we updated our 
previous meta-analysis of 17 studies9 with new information from recently published studies. 
Two authors (PG and SRKS) abstracted the details sought for each marker and any 
discrepancies were resolved through discussion with a third author (SK).  
Within-person variability  
The extent of long-term within person variability in log-transformed cytokine levels was 
assessed based on regression dilution ratios (RDRs) previously reported in the BRHS study16, 17, 
19, 20 or calculated from serial measurements available from 300 participants in the Reykjavik 
study an average of 12 years apart.9 The RDR quantifies the extent to which a single 
measurement of a biomarker reflects the long-term average (i.e. “usual”) level of the 
biomarker, and correction for long-term within person variability in log-transformed cytokine 
levels was achieved dividing the regression coefficients (i.e. log RRs) for association with 
baseline levels by the estimated RDR.32 
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All analyses were conducted using Stata version 11 software (Stata Corp, College Station, 
Texas). 
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Results 
Results from the RCPH cohorts 
Overall, 1514 participants contributed to the analyses comprising 807 participants in the 
randomly sampled sub-cohort and a further 707 incident CHD cases included as part of the 
case-sample enrichment in the case-cohort design.26, 27 Within the random sub-cohort, there 
were 126 incident CHD cases recorded over 12,570 person-years of follow-up (median 9 
years), giving a crude incidence rate of 10 (95% CI: 7 – 12) per 1000 person-years. Hence, in 
total, the analyses involved 833 CHD cases and 681 non-cases. Table 1 summarises the 
participant characteristics by incident CHD status. Compared to non-cases, participants with 
incident CHD were more likely to be older, male, current smokers, and to have diabetes at 
baseline. They also had higher BMI, higher systolic and diastolic blood pressure and higher 
levels of proatherogenic lipids. Loge levels of cytokines were generally higher amongst 
individuals with CHD than those without. CRP measurements were available in half of the 
participants. There were generally weak positive pair-wise correlations between individual 
cytokines (Table 2), with the exception of modest correlations between loge IL-6 and loge TNF-
α (r = 0.22, 95% CI 0.17 – 0.24), and between loge MMP-9 and loge sCD40L (r = 0.31, 95% 
CI 0.26 – 0.37) and stronger correlations between loge CRP and each of loge IL6 (r = 0.48, 
95% CI 0.42 – 0.54) and loge MMP9 (r = 0.31, 95% CI 0.23 – 0.38). Weak correlations were 
also observed between cytokines and other continuous variables, with the exception of 
statistically significant correlations between loge IL-6 and loge IL-18 with age, BMI, HDL-
cholesterol and loge triglycerides; and between loge CRP and the preceding factors plus blood 
pressure (Table 2). Concentrations of most cytokines were generally lower in women than 
men (sCD40L higher), higher among current than never/ex-smokers, lower in current vs. 
never/ex-drinkers, higher in people with vs. without diabetes, and lower in people of higher 
socioeconomic position adjusted for cohort, age, and sex (Table 2). 
There were log-linear relationships between 4 of the cytokines studied and incident CHD risk 
(Figure 1), with the age- and sex-adjusted HRs (95% CI) for all CHD per 1-SD higher log-
transformed levels being 1.37 (1.21, 1.54) for IL-6, 1.26 (1.11, 1.44) for IL-18, 1.30 (1.16, 
1.46) for MMP-9, and 1.13 (1.01, 1.27) for TNF-α, but no association was seen with sCD40L 
[1.01 (0.89, 1.15)]. A modest attenuation in HRs was observed upon additional adjustment for 
several potential confounders (blood pressure, smoking, history of diabetes, BMI, loge 
triglycerides, non-HDL cholesterol, HDL cholesterol, alcohol consumption and socioeconomic 
position), with the adjusted HRs being 1.26 (1.08, 1.46) for IL-6, 1.12 (0.95, 1.31) for IL-18, 
1.21 (1.05, 1.39) for MMP-9, 1.14 (1.00, 1.31) for TNF-α and 0.93 (0.78, 1.11) for sCD40L 
(Table 3). The above findings were similar in analyses restricted to non-fatal MI and CHD 
death outcomes only (Figure 1 and Table 3). In further comparative analyses restricted to 
the smaller subset of participants with information on CRP, somewhat stronger dose-response 
associations were observed for baseline loge CRP than the preceding cytokines (eFigure 1) 
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and, as expected, further adjustment for loge CRP levels more markedly attenuated the 
associations between loge IL-6 and CHD (eTable 3), due to the strong correlation between the 
two (r = 0.48). However, because CRP is downstream of IL-6 in the inflammation pathway, 
such attenuation may be indicative of mediation rather than confounding per se.   
Literature-based meta-analysis 
Including the current study, we found a total of 29 studies eligible for the meta-analysis 
(comprising 25 studies for IL-6 (7 new), 7 studies for IL-18, 5 studies for MMP-9, 3 studies for 
sCD40L, and 7 studies for TNF-α; flow chart in eFigure 2 and study characteristics in eTable 
4). As shown in eTable 4, the new prospective cohort studies involved around 17,000 
participants without known cardiovascular disease at baseline and 3000 incident non-fatal MI 
or CHD death cases and the previous meta-analysis of IL-6 involved 17 studies and 5730 such 
cases.9 The studies were mainly based in general populations in Europe or North America. 
Approximately half of all studies were case-control studies nested within prospective cohorts. 
All studies used the same definition for non-fatal MI or CHD death and ascertainment was 
based on standard criteria, generally involving review of medical records to assess evidence of 
confirmation by cardiac markers, electrocardiograms, and ICD codes among other standard 
diagnostic criteria (eTable 5). In most studies, ELISA was used as the assay method for 
analysing the various inflammatory cytokines (eTable 4), although further information such as 
duration of sample storage and assay reproducibility (coefficient of variation) were infrequently 
reported (eTable 5). Figure 2 shows the forest plot for the updated meta-analysis of 
association of IL-6 and CHD and Figure 3 shows similar findings for the other cytokines. The 
pooled RRs (95% CI) for non-fatal MI or CHD death per 1-SD higher baseline cytokine levels 
adjusted for conventional CHD risk factors were: 1.25 (1.19, 1.32) for IL-6, 1.13 (1.05, 1.20) 
for IL-18, 1.07 (0.97, 1.19) for MMP-9, 1.09 (0.97, 1.19) for sCD40L, and 1.17 (1.09, 1.25) 
for TNF-α (Figure 3). There was no statistically significant between-study heterogeneity 
observed as evidenced by the low I2 statistic, although the power to detect heterogeneity may 
have been limited by the small number of studies available for each cytokine (n≤7), other than 
IL-6 (n=25, including studies in previous meta-analysis,9 Figure 2). Assessment of potential 
bias from small studies suggested there some slight concern for IL-6 (P = 0.024) and MMP-9 
(P = 0.039), although a visual inspection of the degree of asymmetry in the funnel plots 
(eFigure 3) and use of a trim-and-fill procedure31 to assess potential impact suggested that 
the asymmetry may not be of material importance, with the pooled RR estimates expected to 
be 1.19 (1.12, 1.25) for IL-6 and 1.08 (0.97, 1.19) for MMP-9 in the absence of asymmetry. 
 
Correction for long-term within person variability 
The extent of long-term within person variability in levels of the cytokines studied appeared to 
be substantial based on the generally low regression dilution ratios reported by some of the 
published studies (eTable 6). Such variability suggests a potential underestimation of the true 
magnitude of association with non-fatal MI or CHD death, as indicated by comparison of the 
 10
observed associations estimated with baseline levels against those inferred for long-term 
average (“usual”) levels (eFigure 4) based on the pooled regression dilution ratios available 
from the BRHS and Reykjavik studies (eTable 6). 
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Discussion 
The current results indicate that circulating levels of several different pro-inflammatory 
cytokines in initially healthy people are associated with risk of CHD outcomes in an 
approximately log-linear manner. These associations appear to be largely independent of 
several conventional and emerging cardiovascular risk factors. Furthermore, updated meta-
analyses reinforce the validity and generalisability of these new data, suggesting that a 1 SD 
higher baseline level for each of IL-6, IL-18 and TNF-α is associated with about 10-25% higher 
risk of non-fatal MI or CHD death. Analyses that make allowances for the considerable 
fluctuations that we observed of these analytes within individuals over a few years would 
increase the estimated size of these associations with CHD (see below). Similar associations 
have previously been reported for CRP and fibrinogen based on meta-analysis of individual 
participant data,3, 4 hence we only analysed the limited data available on CRP in our primary 
study for making direct internal comparisons. Collectively, the current study establishes robust 
observational associations of several pro-inflammatory cytokines with the risk of CHD, which 
lends further support to the inflammation hypothesis in vascular disease. Although this does 
not establish causality in CHD for any of the analytes, the comprehensive evaluation of their 
associations with CHD should be important, given the evolving literature on cytokines as 
potential drug targets33, 34 and gaps in translating basic scientific findings into clinical practice.1  
IL-6 is involved in the systemic inflammatory response, but also engages in local tissue 
inflammation35 and promotes differentiation of naïve T-helper cells into Th17 cells,36 a cell type 
that has been implicated in auto-immune conditions such as rheumatoid arthritis. TNF-α is a 
pro-inflammatory cytokine, which, similar to IL-6, has been implicated in auto-immune 
diseases.37 Both IL-6 and TNF-α signalling pathways are targets of drugs (such as tocilizumab 
and etanercept) which are used to treat auto-immune diseases.37, 38 Moreover, there have 
been suggestions of an increased incidence of CVD in patients with rheumatoid arthritis,39 and 
non-randomized data from biologic registries suggest TNF-α blocking therapy could reduce 
CVD risk in these patients,37 although such data have well-recognized limitations.40 It is of 
interest, therefore, that two of the agents (ie, canakinumab, a monoclonal antibody to IL-1β, 
and low dose methotrexate) being tested in phase 3 trials of CVD prevention lower circulating 
IL-6 levels,12, 41 while low dose methotrexate therapy also lowers TNF-α levels.12 Furthermore, 
consistent with previous studies, we found circulating IL-18 levels to be positively associated 
with CHD incidence. By contrast, we found no significant associations of sCD40L and MMP-9 
levels with CHD in the aggregate of available prospective studies, suggesting that positive 
findings in previous non-prospective data may have been liable to potential biases, eg, 
"reverse causality".42-45  
Our study had several strengths. First, whereas most previous studies have concurrently 
considered only a few cytokines, we were able to measure simultaneously multiple pro-
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inflammatory cytokines in a common subset of participants in one central laboratory, 
facilitating uniform comparison of the observed associations across markers. Furthermore, we 
excluded all individuals having baseline CVD to minimize any reverse association bias. 
Additionally, we combined data from previously published prospective studies, yielding 
qualitatively similar results to those observed in the new data. Moreover, to help identify 
independent associations, we adjusted for several conventional and emerging risk factors for 
cardiovascular disease, including all the inflammatory cytokines studied (although we 
acknowledge the possibility of "over-adjustment").  
Our study also had potential limitations. First, because we used stored samples, we cannot rule 
out protein degradation between sample collection and assay, especially for self-activable 
enzymes like MMP-9.46 However, randomisation of samples from CHD cases and non-cases 
within assay plates and blinding of laboratory technicians to case/control status of the samples 
should have ensured that samples were treated alike during sample handling and assay. 
Moreover independent studies employing accelerated stability testing protocols have concluded 
that serum samples for determination of cytokines such as IL-6 and sIL-6R can be stored at -
20˚C or less for several years without affecting recovery rates,47 although such evidence was 
lacking for serum levels of the other cytokines we studied. Furthermore, despite known diurnal 
variation in the concentrations of some of the cytokines studied,48 we believe that this would 
also have similarly affected both CHD cases and non-cases. Second, our principal analysis used 
a single baseline measurement of each cytokine to study its association with incident CHD. 
However, our reproducibility sub-studies of cytokine measurements made in the same 
individuals an average of 12 years apart in the Reykjavik9 cohort and 4 years apart in the 
British Regional Heart Study16, 17, 19, 20 suggest that we could have substantially underestimated 
any underlying aetiological associations in CHD. Conversely, the poor reproducibility of some 
cytokines may limit their utility for use in clinical practice as reliable risk indicators based on 
just a single measurement. Third, information on some extensively-studied downstream 
measures of inflammation (such as CRP) was only available in half of the participants in our 
primary study (due to exhaustion of serum samples), which limited the power for direct 
comparisons with other cytokines, besides inability to adequately adjust for the impact of 
differential measurement errors in different cytokines when making such aetiological 
comparisons. Fourth, atherosclerosis and plaque rupture are complex processes involving the 
interplay between several inflammatory substances at different stages of their evolution, hence 
the associations may somewhat differ according to the nature of the endpoints studied. To 
enhance power, we used a composite coronary endpoint as our primary outcome, but sub-
analyses focusing solely on non-fatal MI or CHD death yielded very similar findings to those 
overall. Due to limited information, we could not assess the extent to which the duration of 
sample storage and differences in assay reproducibility may have influenced our meta-analysis 
findings; nevertheless, there was little variation seen in the few reported estimates of assay 
reproducibility. Finally, future observational analyses will wish to evaluate these cytokines in 
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much larger prospective studies with extensive concomitant genetic data to enable causal 
evaluation (eg, Mendelian randomization49). 
In conclusion, several different pro-inflammatory cytokines are each associated with CHD risk 
independent of conventional risk factors and in an approximately log-linear manner. Although 
the current findings lend further support to the inflammation hypothesis in vascular disease, 
causality remains to be established for these cytokines in CHD.
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Table 1. Summary of baseline characteristics of participants by incident CHD status.  
 
 Cases Non-cases Difference† 
Variable n Mean (SD) 
or % 
n Mean (SD) 
or % 
p 
Demographics and lifestyle      
Age at survey (years) 833 57.4 (7.2) 681 48.2 (9.8) <0.0001 
Sex     <0.0001 
   Male 556  67% 334  49%  
   Female 277  33% 347  51%  
Smoking status     <0.0001 
   Never/former 369  44% 373  55%  
   Current 462  56% 306  45%  
Alcohol consumption     0.002 
   Never/former 207  25% 132  19%  
   Current 624  75% 547  81%  
History of diabetes     <0.0001 
   No 699  92% 600  98%  
   Yes 58  8% 13  2%  
Socioeconomic position     0.032 
   Low 167 26% 232 29%  
   Low/Medium 189 30% 235 30%  
   Medium 150 23% 189 24%  
   Medium/High 92 14% 102 13%  
   High 42 7% 36 5%  
Physical measurements      
Systolic blood pressure (mmHg) 832 138 (20) 680 128 (18) <0.001 
Diastolic blood pressure (mmHg) 832 84 (11) 681 81 (10) 0.022 
Pulse rate (count/min) 833 69 (11) 680 67 (10) 0.002 
Body mass index (kg/m2) 827 26 (4.2) 678 25 (4.4) <0.0001 
Lipids      
Total cholesterol (mmol/l) 829 6.63 (1.21) 680 6.14 (1.14) <0.0001 
LDL cholesterol (mmol/l) 809 4.52 (1.09) 670 4.00 (1.02) <0.0001 
Non HDL cholesterol (mmol/l) 827 5.33 (1.23) 677 4.63 (1.16) <0.0001 
HDL cholesterol (mmol/l) 827 1.30 (0.37) 677 1.49 (0.42) <0.0001 
Loge triglycerides (loge mmol/l) 829 0.44 (0.49) 680 0.19 (0.48) <0.0001 
Inflammatory cytokines      
Loge IL-6 (loge ng/l) 732 0.86 (0.67) 594 0.58 (0.68) <0.0001 
Loge IL-18 (loge ng/l) 740 5.71 (0.42) 596 5.55 (0.40) <0.0001 
Loge MMP-9 (loge µg/l) 748 5.97 (0.57) 612 5.87 (0.56) <0.0001 
Loge sCD40L (loge ng/l) 652 8.79 (0.75) 529 8.80 (0.75) 0.938 
Loge TNF-α (loge ng/l) 738 0.43 (0.39) 595 0.40 (0.45) 0.244 
Loge CRP (loge mg/l) 389 0.94 (1.02) 369 0.22 (1.15) <0.0001 
 
† p-value for difference in risk marker distribution between cases and non-cases adjusted for cohort, age, and sex.  
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Table 2. Associations between inflammatory cytokines and CHD risk markers. 
   Partial correlation (95% CI) with row variable or percent difference (95% CI) compared to reference category § 
Variable n Mean (SD) IL-6 (ng/l) IL-18 (ng/l) MMP-9 (µg/l) sCD40L (ng/l) TNF-alpha (ng/l) Log CRP (mg/l) 
Demographics and lifestyle         
Age at survey (years) 1514 52.9 (9.3) 0.28 (0.22, 0.34) 0.15 (0.08, 0.21) 0.01 (-0.05, 0.08) 0.00 (-0.07, 0.08) -0.08 (-0.14, -0.01) 0.24 (0.17, 0.30) 
Sex         
   Male 1514 890 (59%) Ref Ref Ref Ref Ref Ref 
   Female 1514 624 (41%) -10% (-16%, -3%) -16% (-19%, -12%) -5% (-11%, 1%) 30% (20%, 42%) -3% (-7%, 2%) -8% (-22%, 8%) 
Smoking status         
   Never/former 1510 742 (49%) Ref Ref Ref Ref Ref Ref 
   Current 1510 768 (51%) 18% (9%, 26%) 9% (5%, 14%) 32% (25%, 40%) 13% (4%, 23%) 0% (-4%, 5%) 58% (36%, 85%) 
Alcohol consumption         
   Never/former 1510 339 (22%) Ref Ref Ref Ref Ref Ref 
   Current 1510 1171 (78%) -11% (-19%, -2%) -2% (-8%, 3%) 4% (-4%, 12%) 7% (-4%, 19%) -1% (-7%, 5%) -12% (-28%, 8%) 
History of diabetes         
   No 1370 1299 (95%) Ref Ref Ref Ref Ref Ref 
   Yes 1370 71 (5%) 23% (3%, 46%) 3% (-7%, 14%) -9% (-21%, 5%) -8% (-23%, 11%) -3% (-13%, 8%) 57% (6%, 133%) 
Socioeconomic position         
   Low 1434 399 (28%) Ref Ref Ref Ref Ref Ref 
   Low/Medium 1434 424 (30%) -12% (-20%, -3%) -7% (-12%, -1%) -3% (-11%, 5%) -5% (-16%, 7%) -4% (-10%, 2%) -2% (-21%, 20%) 
   Medium 1434 339 (24%) -17% (-25%, -8%) -8% (-14%, -2%) -4% (-12%, 5%) 2% (-10%, 15%) 2% (-5%, 9%) 2% (-20%, 29%) 
   Medium/High 1434 194 (14%) -12% (-22%, 0%) -14% (-20%, -7%) -11% (-20%, -1%) -4% (-17%, 12%) -7% (-14%, 0%) 3% (-22%, 36%) 
   High 1434 78 (5%) -27% (-38%, -13%) -14% (-22%, -5%) -11% (-23%, 3%) 4% (-16%, 29%) -6% (-16%, 5%) -14% (-42%, 28%) 
Physical measurements         
Systolic blood pressure (mmHg) 1512 134 (20) 0.01 (-0.04, 0.06) 0.04 (-0.01, 0.09) -0.04 (-0.09, 0.02) -0.03 (-0.09, 0.02) 0.00 (-0.05, 0.06) 0.15 (0.08, 0.22) 
Diastolic blood pressure (mmHg) 1513 83 (11) 0.01 (-0.05, 0.06) 0.07 (0.02, 0.12) -0.05 (-0.11, -0.00) -0.04 (-0.10, 0.02) 0.03 (-0.03, 0.08) 0.12 (0.05, 0.19) 
Pulse rate (count/min) 1513 68 (11) 0.12 (0.07, 0.17) 0.06 (0.01, 0.12) 0.04 (-0.01, 0.10) 0.01 (-0.05, 0.07) 0.04 (-0.01, 0.10) 0.20 (0.13, 0.27) 
Body mass index (kg/m2) 1505 25.8 (4.3) 0.12 (0.07, 0.18) 0.04 (-0.01, 0.10) -0.02 (-0.08, 0.03) -0.00 (-0.06, 0.06) 0.08 (0.02, 0.13) 0.30 (0.24, 0.37) 
Lipids         
Total cholesterol (mmol/l) 1509 6.41 (1.20) -0.02 (-0.08, 0.03) 0.03 (-0.03, 0.08) 0.02 (-0.04, 0.07) -0.01 (-0.07, 0.04) 0.00 (-0.05, 0.06) 0.05 (-0.02, 0.12) 
LDL cholesterol (mmol/l) 1479 4.29 (1.09) -0.02 (-0.08, 0.03) 0.02 (-0.03, 0.08) 0.03 (-0.02, 0.09) -0.01 (-0.07, 0.04) 0.01 (-0.04, 0.07) 0.05 (-0.02, 0.12) 
Non HDL cholesterol (mmol/l) 1504 5.02 (1.25) 0.02 (-0.03, 0.08) 0.09 (0.03, 0.14) 0.03 (-0.03, 0.08) -0.00 (-0.06, 0.05) 0.04 (-0.02, 0.09) 0.13 (0.06, 0.20) 
HDL cholesterol (mmol/l) 1504 1.39 (0.41) -0.14 (-0.19, -0.09) -0.21 (-0.26, -0.16) -0.03 (-0.09, 0.02) -0.03 (-0.09, 0.02) -0.10 (-0.16, -0.05) -0.23 (-0.30, -0.16) 
Loge triglycerides (loge mmol/l) 1509 0.33 (0.50) 0.11 (0.05, 0.16) 0.20 (0.14, 0.25) 0.03 (-0.02, 0.08) 0.02 (-0.03, 0.08) 0.08 (0.02, 0.13) 0.28 (0.21, 0.34) 
Inflammatory cytokines         
Loge IL-6 (loge ng/l) 1326 0.73 (0.69) - 0.11 (0.06, 0.17) 0.16 (0.11, 0.21) 0.04 (-0.02, 0.09) 0.22 (0.17, 0.27) 0.48 (0.42, 0.54) 
Loge IL-18 (loge ng/l) 1336 5.64 (0.42) 0.11 (0.06, 0.17) - 0.07 (0.02, 0.13) 0.03 (-0.03, 0.09) 0.17 (0.12, 0.23) 0.18 (0.10, 0.26) 
Loge MMP-9 (loge µg/l) 1360 5.93 (0.57) 0.16 (0.11, 0.21) 0.07 (0.02, 0.13) - 0.31 (0.26, 0.37) 0.09 (0.03, 0.14) 0.31 (0.23, 0.38) 
Loge sCD40L (loge ng/l) 1181 8.79 (0.75) 0.04 (-0.02, 0.09) 0.03 (-0.03, 0.09) 0.31 (0.26, 0.37) - 0.10 (0.04, 0.16) 0.10 (0.01, 0.19) 
Loge TNF-α (loge ng/l) 1333 0.42 (0.42) 0.22 (0.17, 0.27) 0.17 (0.12, 0.23) 0.09 (0.03, 0.14) 0.10 (0.04, 0.16) - 0.10 (0.02, 0.17) 
Loge CRP (loge mg/l) 758 0.59 (1.14) 0.48 (0.42, 0.54) 0.18 (0.10, 0.26) 0.31 (0.23, 0.38) 0.10 (0.01, 0.19) 0.10 (0.02, 0.17) - 
§ Partial correlation between levels of cytokine and continuous variables or the percentage difference in mean levels of cytokine compared to reference category for categorical variables adjusted for cohort, age, and sex. 
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Table 3. Hazard ratios for coronary heart disease per 1-SD higher baseline levels of inflammatory cytokines with progressive adjustment for baseline levels of 
potential confounders. 
 
Outcome \ adjustment¶ Loge IL-6 (ng/l) Loge IL-18 (ng/l) Loge MMP-9 (µg/l) Loge sCD40L (ng/l) Loge TNF-α (ng/l) 
 HR (95% CI) Wald χ21 HR (95% CI) Wald χ21 HR (95% CI) Wald χ21 HR (95% CI) Wald χ21 HR (95% CI) Wald χ21 
All CHD (including angina) 1180 participants, 654 cases 1190 participants, 662 cases 1214 participants, 670 cases 1036 participants, 575 cases 1187 participants, 660 cases 
Adjusted for cohort, sex 1.46 (1.30, 1.64) 41 1.37 (1.20, 1.55) 23 1.27 (1.14, 1.42) 18 1.01 (0.88, 1.15) 0 1.06 (0.95, 1.18) 1 
plus age 1.35 (1.18, 1.53) 21 1.29 (1.12, 1.49) 13 1.27 (1.12, 1.44) 14 0.99 (0.85, 1.14) 0 1.13 (1.00, 1.27) 4 
plus systolic blood pressure 1.35 (1.18, 1.53) 20 1.29 (1.11, 1.49) 12 1.26 (1.11, 1.44) 12 1.00 (0.86, 1.16) 0 1.14 (1.01, 1.29) 4 
plus smoking status 1.30 (1.14, 1.49) 15 1.27 (1.10, 1.47) 10 1.20 (1.05, 1.37) 8 0.98 (0.84, 1.14) 0 1.16 (1.02, 1.31) 5 
plus history of diabetes 1.32 (1.15, 1.51) 16 1.25 (1.08, 1.46) 9 1.23 (1.07, 1.41) 9 0.97 (0.83, 1.14) 0 1.17 (1.03, 1.32) 6 
plus BMI 1.30 (1.14, 1.50) 14 1.24 (1.07, 1.44) 8 1.23 (1.07, 1.41) 9 0.97 (0.83, 1.14) 0 1.15 (1.01, 1.31) 5 
plus loge triglycerides 1.27 (1.11, 1.46) 11 1.16 (0.99, 1.36) 4 1.22 (1.06, 1.40) 8 0.96 (0.81, 1.12) 0 1.15 (1.01, 1.31) 4 
plus total cholesterol 1.28 (1.11, 1.47) 12 1.17 (1.00, 1.36) 4 1.22 (1.06, 1.41) 8 0.97 (0.82, 1.14) 0 1.18 (1.03, 1.35) 6 
plus non-HDL cholesterol§ 1.28 (1.11, 1.48) 12 1.15 (0.99, 1.35) 3 1.22 (1.06, 1.40) 8 0.97 (0.82, 1.14) 0 1.17 (1.02, 1.34) 5 
plus HDL cholesterol§ 1.27 (1.11, 1.47) 11 1.12 (0.96, 1.32) 2 1.22 (1.06, 1.40) 8 0.95 (0.80, 1.13) 0 1.14 (1.00, 1.31) 4 
plus alcohol§ 1.27 (1.10, 1.46) 10 1.12 (0.96, 1.32) 2 1.21 (1.06, 1.40) 7 0.95 (0.80, 1.13) 0 1.14 (1.00, 1.31) 4 
plus socioeconomic position§ 1.26 (1.08, 1.46) 9 1.12 (0.95, 1.31) 2 1.21 (1.05, 1.39) 7 0.93 (0.78, 1.11) 1 1.14 (1.00, 1.31) 4 
plus other cytokines§$ 1.24 (1.04, 1.47) 6 1.03 (0.86, 1.23) 0 1.25 (1.05, 1.50) 6 0.80 (0.66, 0.98) 5 1.09 (0.92, 1.30) 1 
           
Non-fatal MI or CHD death 1180 participants, 405 cases 1190 participants, 414 cases 1214 participants, 419 cases 1036 participants, 375 cases 1187 participants, 412 cases 
Adjusted for cohort, sex 1.47 (1.29, 1.67) 34 1.37 (1.18, 1.58) 18 1.27 (1.12, 1.43) 14 1.04 (0.89, 1.22) 0 1.09 (0.96, 1.23) 2 
plus age 1.36 (1.18, 1.56) 19 1.29 (1.10, 1.52) 10 1.26 (1.10, 1.45) 11 1.02 (0.86, 1.21) 0 1.17 (1.02, 1.34) 5 
plus systolic blood pressure 1.36 (1.18, 1.56) 18 1.29 (1.09, 1.52) 9 1.26 (1.09, 1.45) 10 1.03 (0.87, 1.22) 0 1.18 (1.03, 1.36) 6 
plus smoking status 1.31 (1.13, 1.51) 14 1.27 (1.08, 1.50) 8 1.19 (1.03, 1.37) 6 1.02 (0.85, 1.21) 0 1.20 (1.04, 1.38) 7 
plus history of diabetes 1.32 (1.14, 1.52) 14 1.26 (1.06, 1.49) 7 1.22 (1.05, 1.41) 7 1.01 (0.84, 1.21) 0 1.22 (1.06, 1.40) 8 
plus BMI 1.31 (1.13, 1.52) 13 1.25 (1.05, 1.48) 7 1.22 (1.05, 1.41) 7 1.01 (0.84, 1.21) 0 1.21 (1.04, 1.39) 7 
plus loge triglycerides 1.29 (1.11, 1.50) 11 1.17 (0.98, 1.40) 3 1.22 (1.05, 1.41) 7 1.00 (0.84, 1.20) 0 1.19 (1.03, 1.38) 6 
plus total cholesterol 1.30 (1.12, 1.51) 11 1.18 (0.99, 1.40) 3 1.22 (1.05, 1.42) 7 1.02 (0.85, 1.22) 0 1.22 (1.05, 1.42) 7 
plus non-HDL cholesterol§ 1.30 (1.11, 1.51) 11 1.16 (0.97, 1.39) 3 1.21 (1.04, 1.41) 6 1.02 (0.85, 1.23) 0 1.21 (1.04, 1.41) 6 
plus HDL cholesterol§ 1.29 (1.11, 1.50) 11 1.13 (0.95, 1.35) 2 1.21 (1.04, 1.41) 6 1.01 (0.83, 1.22) 0 1.18 (1.02, 1.37) 5 
plus alcohol§ 1.27 (1.09, 1.48) 10 1.13 (0.95, 1.35) 2 1.21 (1.04, 1.40) 6 1.00 (0.83, 1.21) 0 1.18 (1.02, 1.37) 5 
plus socioeconomic position§ 1.29 (1.10, 1.52) 10 1.13 (0.95, 1.36) 3 1.20 (1.03, 1.40) 6 0.98 (0.80, 1.19) 0 1.19 (1.02, 1.39) 5 
plus other cytokines§$ 1.27 (1.06, 1.53) 7 1.06 (0.87, 1.29) 0 1.19 (0.99, 1.43) 3 0.87 (0.70, 1.09) 1 1.12 (0.93, 1.35) 2 
 
¶ Hazard ratios are presented per 1-SD higher observed levels at baseline for each inflammatory cytokine, progressively adjusted as shown and stratified by cohort. The sequence of adjustment generally corresponded to adjustment for 
established non-lipid risk factors first, then lipids (omitting one of highly correlated lipid variables) and finally other lifestyle risk factors and cytokines. Analyses were restricted to participants with complete information on the respective 
inflammatory cytokines and all confounding variables.  
§ Non-HDL cholesterol has been substituted for total cholesterol in these adjusted models 
$ Additional mutual adjustment of the 4 other cytokines based on data from 977 participants and 550 cases for analyses of all CHD outcome, and 355 cases for analysis of non-fatal MI or CHD death outcome. 
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Figure 1. Hazard ratios for all CHD (top panel)† and for non-fatal MI or CHD death (bottom panel)‡ by fifths 
of inflammatory cytokine levels adjusted for age and sex and stratified by cohort.  
 
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1.0
2.0
3.0
4.0
1 82 4 150 600300 200 800400 1500 200005000 2.81.40.7
1 82 4 150 600300 200 800400 1500 200005000 2.81.40.7
IL-6 (ng/l), 732 cases IL-18 (ng/l), 740 cases MMP-9 (µg/l), 748 cases sCD40L (ng/l), 652 cases TNF-alpha (ng/l), 738 cases
IL-6 (ng/l), 450 cases IL-18 (ng/l), 459 cases MMP-9 (µg/l), 464 cases sCD40L (ng/l), 419 cases TNF-alpha (ng/l), 457 cases
(b) Non-fatal MI or CHD death
(a) All CHD
H
az
ar
d 
ra
tio
 (9
5%
 C
I)
Geometric mean, log scale
 
 
† The cut-points defining the fifths of each cytokine were based on the distribution of values observed in the random 
subcohort, so as to be representative of the expected distribution in the population (i.e. avoiding potential bias due to 
purposeful over-sampling of cases in the case-cohort design). Assuming a log-linear relationship the age and sex 
adjusted HR (95% CI) for any CHD per 1-SD higher values were: 1.37 (1.21, 1.54) for IL-6, 1.26 (1.11, 1.44) for IL-18, 
1.30 (1.16, 1.46) for MMP-9, 1.01 (0.89, 1.15) for sCD40L and 1.13 (1.01, 1.27) for TNF-α. 
‡Assuming a log-linear relationship the age and sex adjusted HR (95% CI) for non-fatal MI or CHD death per 1-SD higher 
values were: 1.38 (1.21, 1.57) for IL-6, 1.27 (1.09, 1.47) for IL-18, 1.27 (1.12, 1.45) for MMP-9, 1.03 (0.88, 1.19) for 
sCD40L and 1.17 (1.03, 1.33) for TNF-α. 
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Figure 2. Forest plot for the updated meta-analysis of association of IL-6 and risk of non-fatal MI or CHD 
death in prospective studies adjusted for conventional risk factors*. 
 
 
*In most studies, these included age, sex, smoking status, adiposity markers, blood pressure, and/or lipid markers.  
†Current study.  
£The study reported total number of CVD cases and gave RRs for CHD without stating the number of CHD cases. 
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Figure 3. Meta-analysis of the associations of inflammatory cytokines and risk of non-fatal MI or CHD death 
in prospective studies adjusted for conventional risk factors*. 
 
 
*In most studies, these included age, sex, smoking status, adiposity markers, blood pressure, and/or lipid markers.  
†Current study.  
$The pooled estimate and heterogeneity statistics consider each of the 17 studies in previous IL-6 meta-analysis 
separately (Figure 2). §Relative risk estimates were further adjusted for log C-reactive protein concentrations in this 
study in addition to conventional risk factors.  
¶A proportion of the study participants had prevalent cardiovascular disease at baseline.  
£The study reported total number of CVD cases and gave RRs for CHD without stating the number of CHD cases. 
Abbreviations: BHS, Busselton Health Study; BRHS British Regional Heart Study; BWHHS British Women's Heart and 
Health Study; FINRISK Finnish National Risk Factor Survey; Health ABC Health, Aging, and Body Composition Study; 
PRIME Prospective Epidemiological Study of Myocardial Infarction; RCPH Research Centre for Prevention and Health; 
ULSAM Uppsala Longitudinal Study of Adult Men; WHI-HT Women’s Health Initiative Hormone Trials;. 
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